Literature DB >> 665312

Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission.

G J Dhar, I Bossenmaier, R Cardinal, Z J Petryka, C J Watson.   

Abstract

Transitory renal failure occurred in a patient with acute intermittent porphyria in clinical remission following i.v. administration of 1 000 mg hematin. The clinical and biochemical picture suggested "acute tubular necrosis", which was followed by a prompt and complete return of renal function without any late sequelae. The renal failure is thought to have resulted from the presence of circulating free hematin, formed as a result of rapid administration of such a relatively large amount. Such a complication has not occurred in patients given hematin for acute porphyric relapse, in whom much smaller amounts have been infused.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 665312     DOI: 10.1111/j.0954-6820.1978.tb14903.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  23 in total

1.  Systemic hemin therapy attenuates blood-brain barrier disruption after intracerebral hemorrhage.

Authors:  Xiangping Lu; Jing Chen-Roetling; Raymond F Regan
Journal:  Neurobiol Dis       Date:  2014-06-18       Impact factor: 5.996

2.  Pharmacokinetics of intravenously administered haem arginate.

Authors:  O Tokola; R Tenhunen; L Volin; P Mustajoki
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

Review 3.  Targeting the Nrf2-Heme Oxygenase-1 Axis after Intracerebral Hemorrhage.

Authors:  Jing Chen-Roetling; Raymond F Regan
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

4.  Differential effects of metalloporphyrins on messenger RNA levels of delta-aminolevulinate synthase and heme oxygenase. Studies in cultured chick embryo liver cells.

Authors:  E E Cable; J A Pepe; N C Karamitsios; R W Lambrecht; H L Bonkovsky
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 5.  Management of attacks of acute porphyria.

Authors:  A C Laiwah; K E McColl
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

6.  The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo.

Authors:  K A Nath; J J Haggard; A J Croatt; J P Grande; K D Poss; J Alam
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

7.  Panhematin provides a therapeutic benefit in experimental pancreatitis.

Authors:  Aida Habtezion; Raymond Kwan; Ehsaan Akhtar; Stephen P Wanaski; Stephen D Collins; Ronald J Wong; David K Stevenson; Eugene C Butcher; M Bishr Omary
Journal:  Gut       Date:  2010-12-15       Impact factor: 23.059

8.  Hematin therapy in porphyric attacks.

Authors:  C A Pierach; I Bossenmaier; R Cardinal; M Weimer; C J Watson
Journal:  Klin Wochenschr       Date:  1980-08-15

9.  The "glucose effect" in acute hepatic porphyrias and in experimental porphyria.

Authors:  M Doss; F Verspohl
Journal:  Klin Wochenschr       Date:  1981-07-01

10.  Incorporation of haemoglobin haem into the rat hepatic haemoproteins tryptophan pyrrolase and cytochrome P-450.

Authors:  J F Wyman; J L Gollan; W Settle; G C Farrell; M A Correia
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.